ライフサイエンスコーパス: in the treated group

1 eclampsia, shoulder dystocia, and macrosomia in the treated group.

2 ures of efficacy also showed better outcomes in the treated group.

3 t decrease (P < .05) in vasomotor reactivity in the treated group.

4 educed fibrosis and greater vascular density in the treated group.

5 ; and TUNEL assay showed decreased apoptosis in the treated group.

6 21 of the 22 patients, and were less intense in the treated group.

7 -diastolic volume to body weight was reduced in the treated group.

8 perplasia, granuloma, or collagen deposition in the treated groups.

9 al evidence of protection from immune attack in the treated groups.

10 t in circulating antibody also were detected in the treated groups.

11 progression of left ventricular dysfunction in the "treated" group.

12 y loss and visual analog pain scale improved in the treated group (-1.5 vs -0.5; p = 0.01).

13 rly, the Shannon's alpha-diversity was lower in the treated group (10.60; 95% CI, 8.82-12.36) than th

14 ut the number of SAEs per patient was higher in the treated group (2.7 versus 1.3; P = 0.003).

15 BLFB were significantly increased (p<0.001) in the treated group (25.84+/-1.41%) compared with the c

16 In the treated group, 25(OH)D(total) rose from 18 +/- 7

17 Significantly fewer patients in the treated group (31%) compared with the placebo gro

18 rd fewer people on average reported headache in the treated groups (8.0%) than the placebo groups (12

19 In the treated group, a higher dose of a typical neurole

20 In the treated group, a mAb to the CD11d subunit of the

21 cular resistance decreased by 21% (P < .001) in the treated group; a significant (22%) increase of th

22 VA and VF parameters tended to be worse in the treated group, although without statistical signi

23 In the treated group, an adenoviral vector carrying the

24 infection were 0.018 episodes/patient-month in the treated group and 0.012 episodes/patient-month in

25 rejection were 0.031 episodes/patient-month in the treated group and 0.029 episodes/patient-month in

26 rejection were 0.070 episodes/patient-month in the treated group and 0.032 episodes/patient-month in

27 rejection were 0.044 episodes/patient-month in the treated group and 0.035 episodes/patient-month in

28 f isolated grade 2 rejection was 15.6 months in the treated group and 17.8 months in the nontreated g

29 For vitamin E, there were 197 cases in the treated group and 192 in the placebo group (hazar

30 One eye in the treated group and 2 eyes in the control group had

31 and 10 years was 69% and 51 %, respectively, in the treated group and 67% and 41 %, respectively, in

32 ract surgery-related complications was 8.61% in the treated group and 8% in the control group (not si

33 8, 23, and 26, respectively, in the 3 babies in the treated group and at week 19 in the baby in the c

34 zed myasthenia developed in 8 of 76 patients in the treated group and in 15 of 82 patients in the non

35 control group were significantly attenuated in the treated group, as was thrombosis of renal glomeru

36 unotherapy, sIgE was significantly decreased in the treated groups compared to sham (P < 0.001), wher

37 bitors showed a 20% to 30% decrease in Bcl-X in the treated groups compared with controls.

38 tolic pressure (Ps), DevP, and (+dP/dt)/DevP in the treated groups compared with the control group.

39 gilance for threat information was decreased in the treated group, compared with the waiting group, t

40 efficient (ADC) measured by DW-MRI increased in the treated group consistent with cytotoxic edema.

41 Because the reduction of metastasis seen in the treated group could have resulted from 2-fold red

42 Monkeys in the treated group demonstrated prolonged graft surviv

43 Patients in the treated group had a significantly thinner choroid

44 rbation rates were low, but there were fewer in the treated group (hazard ratio, 0.74; 95% confidence

45 In the treated groups, hearts were perfused with ranolaz

46 ed by non-targets was significantly enhanced in the treated group, indicating memantine-associated im

47 f the gut microbiome was significantly lower in the treated group (inverse Simpson's alpha-diversity,

48 atients in the untreated group, the patients in the treated group mounted a 6-fold increased HIV-1 p2

49 in the control group compared with -5 +/- 5% in the treated group (p < 0.03).

50 /kg in control animals to +0.5 +/- 0.8 ml/kg in the treated group (p < 0.04).

51 r the break point the slope became shallower in the treated group (P = 0.002).

52 t the 0.22-mm radius decreased significantly in the treated group (P = 0.005).

53 For any infarct size, LVEF was greater in the treated group (p = 0.045).

54 wet wt in controls to 0.58+/-0.12 U/g wet wt in the treated group (P<0.001).

55 in controls to 15.1+/-1.2 micromol/g dry wt in the treated group (P<0.01), and myeloperoxidase activ

56 mean+/-SEM) in controls to 118.1+/-8.2 mm Hg in the treated group (P<0.05), ATP increased from 11.0+/

57 ntrol groups compared with only 95 of 13,389 in the treated groups progressed from less severe to sev

58 t was not protective and increased morbidity in the treated group, suggesting that P-PMO may cause to

59 ta-galactosidase activity was 10-fold higher in the treated group than in controls (P<0.0001).

60 lower at 80 MPa after vitrification-warming in the treated groups than controls.

61 In the treated group, there was a significant reduction

62 In the treated group, there were also significant differ

63 nge in CPT scores was -3.0 (range, -6 to +3) in the treated group versus +1.0 in the controls (range,

64 ment analysis indicated 0% of HBsAg+ infants in the treated group versus 2.84% in the NTx group (P=0.

65 (0 of 20 animals with CNS metastatic disease in the treated group versus 4 of 20 animals with CNS dis

66 transplanted patients, there were no deaths in the treated group versus 6 deaths in the control grou

67 asion (1 of 20 animals with invasive disease in the treated group versus 7 of 20 animals with invasiv

68 py, the resting regional cerebral blood flow in the treated group was significantly reduced, with a n

69 In addition, progeny in the treated group were injected subcutaneously every

70 was administered at the time of reperfusion in the treated group, whereas saline was administered to

71 ibroblast growth factor proteins were higher in the treated group, whereas VEGF receptor 2 (Flk-1), a